BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

...to its toolbox through a pair of deals (see “Pair of Trispecific Deals” ). From Harpoon Therapeutics Inc....
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...in include neoantigen T cell therapy company Pact Pharma Inc.; next-generation T cell engager play Harpoon Therapeutics Inc....
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...No. 7508 ). Trispecific engager platforms may also offer early hints of efficacy at ASCO. Harpoon Therapeutics Inc....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...join the board. Bethell was CSO of Medivir AB (SSE:MVIR B); Sacks is CMO of Harpoon Therapeutics Inc....
BioCentury | Nov 22, 2019
Company News

In pair of trispecific deals, AbbVie expands access to Harpoon tech, gains NK cell engagers

...with Dragonfly, could mark the pharma’s entrance into NK cell engagers. Under the deal with Harpoon Therapeutics Inc....
...with Celgene Corp. and Merck & Co. Inc. (NYSE:MRK). Elizabeth S. Eaton, Staff Writer AbbVie Inc. Dragonfly Therapeutics Inc. Harpoon Therapeutics Inc. trispecific T...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Inc. (NASDAQ:TCRR) 2/13/19 $86.3 $359.1 $342.6 -5% Avedro Inc. (NASDAQ:AVDR) 2/13/19 $70.0 $238.8 $336.0 41% Harpoon Therapeutics Inc....
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...ADC Therapeutics S.A. / AstraZeneca plc (LSE:AZN; NYSE:AZN) MEDI3726 Ph I/II Monotherapy and Xtandi None Harpoon Therapeutics Inc....
BioCentury | Feb 22, 2019
Finance

MPM keeps building

...said the firm used OIF and BioVentures 2014 to co-invest in companies including cancer plays Harpoon Therapeutics Inc....
BioCentury | Feb 13, 2019
Financial News

Harpoon slips after pricing $75.6M IPO

...end of the government shutdown (see "Broken Window" ). Harpoon Therapeutics Inc. (NASDAQ:HARP), South San Francisco, Calif. Paul Bonanos Harpoon Therapeutics Inc....
BioCentury | Feb 8, 2019
Financial News

Harpoon slips after pricing $75.6M IPO

...have resumed on NASDAQ following the end of the government shutdown (see "Broken Window" ). Paul Bonanos Harpoon Therapeutics Inc. IPO...
Items per page:
1 - 10 of 35
BioCentury | Jun 11, 2020
Deals

In course correction, AbbVie steers toward innovation with Genmab deal

...to its toolbox through a pair of deals (see “Pair of Trispecific Deals” ). From Harpoon Therapeutics Inc....
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

...in include neoantigen T cell therapy company Pact Pharma Inc.; next-generation T cell engager play Harpoon Therapeutics Inc....
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

...No. 7508 ). Trispecific engager platforms may also offer early hints of efficacy at ASCO. Harpoon Therapeutics Inc....
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...join the board. Bethell was CSO of Medivir AB (SSE:MVIR B); Sacks is CMO of Harpoon Therapeutics Inc....
BioCentury | Nov 22, 2019
Company News

In pair of trispecific deals, AbbVie expands access to Harpoon tech, gains NK cell engagers

...with Dragonfly, could mark the pharma’s entrance into NK cell engagers. Under the deal with Harpoon Therapeutics Inc....
...with Celgene Corp. and Merck & Co. Inc. (NYSE:MRK). Elizabeth S. Eaton, Staff Writer AbbVie Inc. Dragonfly Therapeutics Inc. Harpoon Therapeutics Inc. trispecific T...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

...Inc. (NASDAQ:TCRR) 2/13/19 $86.3 $359.1 $342.6 -5% Avedro Inc. (NASDAQ:AVDR) 2/13/19 $70.0 $238.8 $336.0 41% Harpoon Therapeutics Inc....
BioCentury | Mar 1, 2019
Product Development

Prostate cancer disrupted

...ADC Therapeutics S.A. / AstraZeneca plc (LSE:AZN; NYSE:AZN) MEDI3726 Ph I/II Monotherapy and Xtandi None Harpoon Therapeutics Inc....
BioCentury | Feb 22, 2019
Finance

MPM keeps building

...said the firm used OIF and BioVentures 2014 to co-invest in companies including cancer plays Harpoon Therapeutics Inc....
BioCentury | Feb 13, 2019
Financial News

Harpoon slips after pricing $75.6M IPO

...end of the government shutdown (see "Broken Window" ). Harpoon Therapeutics Inc. (NASDAQ:HARP), South San Francisco, Calif. Paul Bonanos Harpoon Therapeutics Inc....
BioCentury | Feb 8, 2019
Financial News

Harpoon slips after pricing $75.6M IPO

...have resumed on NASDAQ following the end of the government shutdown (see "Broken Window" ). Paul Bonanos Harpoon Therapeutics Inc. IPO...
Items per page:
1 - 10 of 35